News Feature in 2019

In one year, George Church’s group spun out 16 different startups. What explains the lab’s incredible output of entrepreneurs?

Adult stem cell companies are pivoting their businesses to commercialize exosomes as therapeutics.

The devastating diagnosis of a rare disease is prompting an increasing number of people to go to the bench and take research into their own hands

Despite dazzling lab demonstrations, robust and viable clinical interventions using brain–computer interfaces remain some way off.

Non-invasive stimulation of the brain is being touted to promote health and well-being and for ‘curing’ disease, but the mechanistic underpinnings of the devices remain unclear.

Millions of people each year are giving up their genotype information for research, for health, for fun and now for profit.

As issues of product consistency, standardization and specificity are being tackled, can phage therapeutics—long oversold and overhyped—finally realize their antibacterial potential?

Realizing the dream of noninvasive glucose monitoring

NASH has replaced hepatitis C as the most important nonalcoholic liver disease. Biotech and pharma are racing to tap into this enormous market.

The FDA approved record numbers of new molecular entities, orphan drugs, small-molecule generics and biosimilars in 2018. Could industry’s regulatory success of the past two years become the new normal?

As clinical evidence mounts demonstrating the power of combining oncolytic viruses and checkpoint inhibitors, companies are scrambling to get in on the action.